A total of 6 patients had evaluable tissue for IHC analysis of GRM1, 4 of which (patient 23 with sarcoma, patient 33 with acinar cell pancreas, patients 2 and 26 with melanoma) showed statistically significant (p < 0.05) decrease in GRM1 expression from pre- to post-treatment tissue (Figure 3C, Supplementary Table 5). This evidence concerns the gene GRM1 and melanoma.